SB1414 amends Section 351(k)(2)(A) of the Public Health Service Act to change what clinical studies a biosimilar applicant must include. The bill makes pharmacokinetic studies the baseline requirement and removes any automatic requirement to assess immunogenicity, pharmacodynamics, or comparative clinical efficacy; the Secretary of HHS may still require those assessments but only after issuing written notice and justification no later than the earliest date the applicant may file.
For developers, payers, and regulators this is a procedural shift that lowers the default prelicensure evidentiary bar for many biosimilars and creates a predictable deadline for the FDA to require additional clinical work. The tradeoffs are faster, cheaper entry for some biosimilars against potential gaps in premarket safety and effectiveness data that otherwise would be captured by immunogenicity or comparative clinical studies.
At a Glance
What It Does
The bill rewrites the clinical‑study requirement in 42 U.S.C. 262(k)(2)(A) so that a biosimilar applicant must, at minimum, submit pharmacokinetic studies sufficient to show safety, purity, and potency and may submit clinical studies demonstrating safety/purity/potency for appropriate conditions of use. Assessments of immunogenicity, pharmacodynamics, or comparative clinical efficacy are not automatically required; the Secretary may require them but must give written justification by the earliest possible filing date.
Who It Affects
Biosimilar developers using the 351(k) pathway, originator biologic sponsors, the FDA/HHS (which gains a new pre‑filing notice obligation), clinical trial sponsors and CROs, and downstream payers and health systems that depend on prelicensure evidence to guide formulary and treatment decisions.
Why It Matters
By narrowing default prelicensure requirements and forcing early notice for additional data demands, the bill aims to speed biosimilar approvals and lower development cost, but it also shifts more of the safety‑signal burden into either narrower premarket datasets or postmarket surveillance. The change could alter sponsor development plans, global regulatory alignment, and the clinical evidence available at launch.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB1414 targets the statutory checklist of clinical proof a company must submit when seeking approval of a biosimilar under Section 351(k). The bill edits the statutory language to make pharmacokinetic (PK) studies the baseline clinical evidence required to demonstrate safety, purity, and potency.
It then retains a separate slot for clinical study or studies that demonstrate those same attributes in one or more appropriate use conditions, but explicitly makes other specific assessments—immunogenicity, pharmacodynamics (PD), and comparative clinical efficacy—non‑mandatory by default.
The bill adds a new clause that preserves the Secretary of HHS’s authority to require those non‑mandatory assessments. Crucially, the Secretary may exercise that authority only after making a determination and must provide the applicant with notice that includes a written justification of the basis for requiring immunogenicity, PD, or comparative efficacy assessment.
That notice must be provided not later than the earliest date on which the applicant may file a 351(k) application, creating a firm pre‑filing deadline for FDA to set a higher evidentiary bar.The change applies only to 351(k) applications submitted on or after the bill’s enactment. The statutory text does not alter other features of the biosimilar framework—there is no amendment to the standards for interchangeability, exclusivity periods, patent litigation procedures, or postmarket requirements—so sponsors must read this change in the context of the broader 351(k) pathway.
Practically, sponsors will get a clearer signal before filing whether the FDA will demand larger clinical packages, but they must still plan for the possibility that the Secretary will use discretion to require additional studies for particular products or indications.Implementation will hinge on how the Secretary defines the ‘‘earliest date on which the applicant may file’’ and what counts as a sufficient written justification. Regulators and sponsors will need to coordinate on timing, likely via pre‑IND and pre‑BLA meetings, because the statute converts what has often been an iterative, pre‑ and post‑submission negotiation into a hard pre‑submission notice requirement.
The bill therefore increases predictability but also raises consequential questions about postmarket surveillance and how regulators will monitor immunogenicity and other safety signals if fewer prelicensure studies are required.
The Five Things You Need to Know
SB1414 amends 42 U.S.C. 262(k)(2)(A) — the statutory clinical‑study list for 351(k) biosimilar applications.
The bill makes pharmacokinetic studies the default mandatory clinical evidence to demonstrate safety, purity, and potency.
Assessments of immunogenicity, pharmacodynamics, and comparative clinical efficacy are no longer automatically required; they become discretionary.
The Secretary may require those discretionary assessments only after issuing written notice and justification to the applicant by the earliest date the applicant can file a 351(k) application.
The change applies to 351(k) applications submitted on or after the date of enactment; earlier applications are unaffected.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — 'Expedited Access to Biosimilars Act'
This is the caption for the statute and has no operative effect on substance or procedure; it signals the legislative intent to accelerate biosimilar access, which matters for interpreting legislative purpose but does not change regulatory mechanics.
Rewrites required clinical‑study items and emphasizes pharmacokinetics
The bill replaces the statutory items to specify that a biosimilar applicant must submit pharmacokinetic studies sufficient to demonstrate safety, purity, and potency and must submit clinical study(ies) adequate to demonstrate those attributes in one or more appropriate uses. That restructuring narrows the list of mandatory assessments and elevates PK as the core, non‑waivable element of the prelicensure clinical package.
Secretary discretion contingent on pre‑filing notice and written justification
This new clause preserves HHS/FDA authority to require immunogenicity, PD, or comparative efficacy studies but conditions that authority on a written determination and notice to the applicant not later than the earliest filing date. Practically, the agency loses the ability to impose new trial requirements after filing unless it provided a timely justification, shifting the timing of major evidentiary decisions to pre‑submission interactions.
Applies only to 351(k) submissions filed after enactment
The statute explicitly limits the amendments to applications submitted on or after enactment, which avoids retroactive alteration of pending or previously decided filings but means sponsors planning future development will need to account for the new default and the timing constraint on agency requests.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Biosimilar developers, especially smaller firms — Lowering mandatory clinical requirements reduces trial cost and time, making more candidates economically viable and accelerating market entry for sponsors that can rely primarily on PK and analytical comparability.
- Payers and purchasers (insurers, PBMs, health systems) — Faster biosimilar launches and lower development costs can translate into earlier price competition and increased bargaining leverage.
- Investors and contract research organizations focusing on analytical and PK work — Demand shifts toward assay development, comparative analytical packages, and PK trials rather than large comparative efficacy trials.
- Some patients — Those whose physicians adopt biosimilars sooner may gain earlier access to lower‑cost alternatives when formulary and prescribing practices follow.
Who Bears the Cost
- FDA/HHS — The agency must produce timely written justifications and make determinations before the earliest filing date, adding procedural workload and potential legal exposure if its justifications are challenged; it may also need expanded postmarket surveillance resources.
- Patients and clinicians concerned about rare immune reactions — With fewer mandatory immunogenicity or comparative efficacy studies before licensure, early prescribing may occur with less premarket evidence on those specific risks.
- Originator biologic sponsors — Increased likelihood of faster biosimilar entrants could accelerate revenue loss and intensify patent and litigation activity as originators defend market share.
- Sponsors of biosimilars that would have relied on PD or comparative efficacy data — Those programs may need to retool development plans (or perform studies anyway) if the agency still requires additional data for certain products, creating planning uncertainty.
- Clinical trial sites and CROs that specialize in large comparative efficacy studies — Demand for large, long trials may fall, shifting revenue to other types of work and potentially leaving capacity underutilized.
Key Issues
The Core Tension
The central dilemma is speed versus certainty: the bill advances faster, cheaper access to biosimilars by lowering the default prelicensure evidentiary bar, but that same move reduces the amount of premarket clinical evidence on immunogenicity and comparative outcomes—potentially increasing reliance on postmarket surveillance and clinical judgment to detect and manage safety or effectiveness differences.
The bill creates a practical predictability tradeoff: applicants gain clarity because the agency must say, before the earliest filing opportunity, whether it will demand immunogenicity, PD, or comparative efficacy studies. But the statute leaves important definitions undefined — notably what constitutes ‘‘the earliest date on which the applicant may file’’ and what a legally sufficient written justification must include.
Those ambiguities will drive disputes and require FDA guidance or adjudication. If ‘‘earliest filing date’’ is interpreted narrowly, FDA could be boxed into early determinations before full analytical comparability packages are developed; if interpreted broadly, applicants may receive little practical benefit.
Another implementation tension concerns safety monitoring. Reducing prelicensure immunogenicity and comparative efficacy assessments shifts detection of some adverse events into the postmarket period.
The statute does not add new postmarket surveillance resources, nor does it amend REMS or pharmacovigilance authorities to compensate. That gap raises questions about whether sponsors and regulators will fill evidence shortfalls voluntarily, through real‑world data studies, or by continuing to require additional premarket studies under the Secretary’s discretion for higher‑risk products.
Finally, the bill omits any change to interchangeability or exclusivity rules; it changes only the evidentiary baseline for licensure, which means stakeholders will need to map this statutory change onto existing patent‑litigation and substitution pathways to understand commercial effects.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.